Grace Therapeutics, Inc. Restructuring and Related Cost, Cost Incurred to Date
Grace Therapeutics, Inc. (GRCE) had Restructuring and Related Cost, Cost Incurred to Date of $0 as of 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Notes
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2024-08-09
- 2024-06-30: Restructuring and Related Cost, Cost Incurred to Date $0.00.
- 2023-06-30: Restructuring and Related Cost, Cost Incurred to Date $1.49M; Restructuring and Related Cost, Cost Incurred to Date as first filed $274.00K.
- 2023-05-08: Restructuring and Related Cost, Cost Incurred to Date $1.49M.
- 2023-03-31: Restructuring and Related Cost, Cost Incurred to Date $1.49M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date | Restructuring and Related Cost, Cost Incurred to Date as first filed |
|---|---|---|
| 2024-06-30 | $0.00 10-Q · filed 2024-08-09 | |
| 2023-06-30 | $1.49M 10-Q · filed 2024-08-09 | $274.00K 10-Q · filed 2023-08-11 |
| 2023-05-08 | $1.49M 10-K · filed 2024-06-21 | |
| 2023-03-31 | $1.49M 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |